• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
RHY
Click for more information
8.57% 6.4¢

RHYTHM BIOSCIENCES LIMITED - Announcements

Market Cap $15.41M  ! watchlist Created with Sketch. Add to my watchlist

Rhythm Biosciences Ltd is an Australia-based medical diagnostics company. The Company is... Rhythm Biosciences Ltd is an Australia-based medical diagnostics company. The Company is engaged in delivering simple, affordable blood tests for accurate and early detection of cancers. It is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives. The Company has developed ColoSTAT, a blood test for the detection of Colorectal Cancer (CRC). If diagnosed early, colorectal cancer is curable. The ColoSTAT Test-Kit measures five specific protein biomarkers that indicate the likelihood of CRC. The test is an alternative for individuals who are unable or unwilling to participate in current screening programs. It is being updated to meet the IVDR (In vitro diagnostic medical devices regulation) regulatory standards. It is focused on working with likeminded global partners to achieve commercialization and distribution of these simple solutions.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
Filters [Clear]
  • Price Sensitive: Yes
RHY Rhythm recruits first patient in ColoSTAT clinical trialPRICE SENSITIVE18/03/19
RHY Appendix 4D and Half Yearly Report and AccountsPRICE SENSITIVE26/02/19
RHY RHY Signs first ColoSTAT site for Clinical Trial - Study 7PRICE SENSITIVE20/02/19
RHY Corporate PresentationPRICE SENSITIVE11/02/19
RHY Appendix 4CPRICE SENSITIVE29/01/19
RHY Rhythm Completes Reagent Development ProgramPRICE SENSITIVE05/12/18
RHY Appointment of CEO - Senior Management ChangesPRICE SENSITIVE28/11/18
RHY AGM PresentationPRICE SENSITIVE26/11/18
RHY Appendix 4CPRICE SENSITIVE29/10/18
RHY Final Antibody Selection CompletePRICE SENSITIVE03/10/18
RHY Appendix 4EPRICE SENSITIVE31/08/18
RHY Appendix 4CPRICE SENSITIVE30/07/18
RHY Rhythm completes cloning of key reagent ahead of schedulePRICE SENSITIVE21/06/18 download Created with Sketch. 74.01KB
RHY Rhythm Granted Biomarker Patent in EuropePRICE SENSITIVE16/05/18
RHY RHY's Four Antibodies Pass all Three Key Screening TestsPRICE SENSITIVE14/05/18
RHY Appendix 4CPRICE SENSITIVE30/04/18
RHY Reagent Development UpdatePRICE SENSITIVE24/04/18
RHY Appendix 4D - Half Yearly ReportPRICE SENSITIVE01/03/18
RHY Rhythm reports reagent development updatePRICE SENSITIVE07/02/18
RHY Quarterly report and Appendix 4CPRICE SENSITIVE31/01/18
RHY CSIRO and Rhythm Commence Development of Key ReagentsPRICE SENSITIVE24/01/18
RHY CSIRO to assist Rhythm Biosciences develop key reagentsPRICE SENSITIVE09/01/18
RHY Admission to Official ListPRICE SENSITIVE06/12/17
RHY Rhythm recruits first patient in ColoSTAT clinical trial
18/03/19PRICE SENSITIVE
RHY Appendix 4D and Half Yearly Report and Accounts
26/02/19PRICE SENSITIVE
RHY RHY Signs first ColoSTAT site for Clinical Trial - Study 7
20/02/19PRICE SENSITIVE
RHY Corporate Presentation
11/02/19PRICE SENSITIVE
RHY Appendix 4C
29/01/19PRICE SENSITIVE
RHY Rhythm Completes Reagent Development Program
05/12/18PRICE SENSITIVE
RHY Appointment of CEO - Senior Management Changes
28/11/18PRICE SENSITIVE
RHY AGM Presentation
26/11/18PRICE SENSITIVE
RHY Appendix 4C
29/10/18PRICE SENSITIVE
RHY Final Antibody Selection Complete
03/10/18PRICE SENSITIVE
RHY Appendix 4E
31/08/18PRICE SENSITIVE
RHY Appendix 4C
30/07/18PRICE SENSITIVE
RHY Rhythm completes cloning of key reagent ahead of schedule
21/06/18PRICE SENSITIVE download Created with Sketch. 74.01KB
RHY Rhythm Granted Biomarker Patent in Europe
16/05/18PRICE SENSITIVE
RHY RHY's Four Antibodies Pass all Three Key Screening Tests
14/05/18PRICE SENSITIVE
RHY Appendix 4C
30/04/18PRICE SENSITIVE
RHY Reagent Development Update
24/04/18PRICE SENSITIVE
RHY Appendix 4D - Half Yearly Report
01/03/18PRICE SENSITIVE
RHY Rhythm reports reagent development update
07/02/18PRICE SENSITIVE
RHY Quarterly report and Appendix 4C
31/01/18PRICE SENSITIVE
RHY CSIRO and Rhythm Commence Development of Key Reagents
24/01/18PRICE SENSITIVE
RHY CSIRO to assist Rhythm Biosciences develop key reagents
09/01/18PRICE SENSITIVE
RHY Admission to Official List
06/12/17PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
6.4¢ 		Change
-0.006(8.57%) 		Mkt cap ! $15.41M
Open High Low Value Volume
7.1¢ 7.4¢ 6.2¢ $26.95K 399.8K

Buyers (Bids)

No. Vol. Price($)
1 30000 6.4¢
 

Sellers (Offers)

Price($) Vol. No.
7.6¢ 12800 1
View Market Depth
Last trade - 11.54am 30/09/2024 (20 minute delay) ?
Last
6.2¢ 		  Change
-0.006 ( 15.1 %)
Open High Low Volume
7.3¢ 7.3¢ 6.2¢ 177200
Last updated 10.54am 30/09/2024 ?
RHY (ASX) Chart

Top Stories

Zenith's sale of Develin Creek delivers $975K cash, with shares up 13%

Zenith Minerals Ltd has completed its sale of Develin Creek copper-zinc project in Queensland to QMines Ltd
Hastings progressing Yangibana to production with lower costs Hastings Technology Metals Ltd has released its annual report to shareholders, saying that it has reduced capital costs by $56 million
Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia Coda Minerals (ASX:COD) CEO, Chris Stevens, joins The Market Online to discuss the company's current rights issue, and how the capital from this raise will be used to further its copper exploration in South Australia. In addition, Chris talks through the journey the company has taken over the last few years since listing until now.
The iron ore comeback: Can it last? The Chinese need our iron ore and we could do with the cash if we are sensible enough to put the stuff on a boat and sell it to them.
Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical trials with new capital.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.